Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)
We recently compiled a list of the 5 Stocks Jensen Huang’s Company is Betting On. In this article, we are going to take a ...
Altitude Lab Startups Raise $154M in Capital
Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse ...
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...
SoftBank adds to shares in VTEX, YMM, cuts NMRA and exits DASH, among other moves
The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...
Zacks.com on MSN5d
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, ...
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Hosted on MSN5d
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $8.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...